GlassScriptPhysician profile
John Dulemba
NPI 1982784211
$12,208.16
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,768 · 2020: $3,223 · 2021: $611 · 2022: $2,312 · 2023: $3,273 · 2024: $21.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,650 · Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,650.00 |
| Food and Beverage | $644.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $4,478.47 | 2021-2023 | Biofix, Biodrestore |
| Lumenis, INC | $4,050.48 | 2019-2020 | |
| Lumenis LTD. | $1,340.00 | 2019 | |
| Abbvie INC. | $317.50 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Aspira Women'S Health INC | $280.24 | 2021-2023 | Ova1 |
| Allergan, INC. | $256.07 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $235.53 | 2019-2021 | |
| Boston Scientific Corporation | $153.76 | 2020-2024 | Wavewriter Alpha Prime 16 |
| Caldera Medical, INC | $150.24 | 2022 | |
| Medtronic, INC. | $123.33 | 2023 | Interstim |
| Gynesonics, INC. | $95.20 | 2022 | |
| Pfizer INC. | $85.96 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $64.64 | 2020-2022 | |
| Astellas Pharma US INC | $59.95 | 2023 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $56.19 | 2022-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Northgate Technologies, INC. | $54.70 | 2022-2023 | Smoke Removel - Nebulae |
| Currax Pharmaceuticals LLC | $53.38 | 2019-2022 | |
| Monaghan Medical Corporation | $52.89 | 2023 | Aerochamber, Aeroeclipse |
| Becton, Dickinson and Company | $33.43 | 2021-2022 | |
| Therapeuticsmd, INC. | $29.49 | 2019-2021 | |
| Novo Nordisk INC | $27.39 | 2019-2020 | |
| Teleflex LLC | $27.11 | 2023 | Deknatel |
| Lupin INC. | $26.04 | 2019 | |
| Millicent US INC | $23.52 | 2020 | |
| Exeltis, USA INC. | $21.10 | 2023 | Slynd |
| Merck Sharp & Dohme LLC | $19.60 | 2021 | |
| Baxter Healthcare | $19.36 | 2023 | Adept |
| Myovant Sciences INC. | $18.80 | 2021 | |
| Lsi Solutions INC | $16.19 | 2019 | |
| Axonics, INC. | $14.93 | 2020 | |
| Bausch Health US, LLC | $13.40 | 2019 | |
| Channel Medsystems, INC. | $9.27 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dulemba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.